GNPX - ジェンプレックス (Genprex Inc.)

GNPXのニュース

   Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview  2020/03/05 13:05:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's newly licensed gene therapy for diabetes explained by lead researcher in new video.
   Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes  2020/02/11 13:17:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex licenses patented diabetes gene therapy from University of Pittsburgh.
   Genprex to Present at NobleCon16 Investor Conference  2020/02/03 13:17:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's CEO will present at the upcoming Noble Capital Market's annual investor conference.
   Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy  2020/01/29 13:18:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's TUSC2 gene found to be a potential biomarker for thyroid cancer.
   Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering  2020/01/28 13:00:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex closes $8 million offering.
   Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview  2020/03/05 13:05:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's newly licensed gene therapy for diabetes explained by lead researcher in new video.
   Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes  2020/02/11 13:17:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex licenses patented diabetes gene therapy from University of Pittsburgh.
   Genprex to Present at NobleCon16 Investor Conference  2020/02/03 13:17:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's CEO will present at the upcoming Noble Capital Market's annual investor conference.
   Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy  2020/01/29 13:18:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's TUSC2 gene found to be a potential biomarker for thyroid cancer.
   Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering  2020/01/28 13:00:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex closes $8 million offering.
   Genprex to Present at NobleCon16 Investor Conference  2020/02/03 13:17:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's CEO will present at the upcoming Noble Capital Market's annual investor conference.
   Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy  2020/01/29 13:18:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex's TUSC2 gene found to be a potential biomarker for thyroid cancer.
   Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering  2020/01/28 13:00:00 Business Wire
AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex closes $8 million offering.
   Genprex: Prepare For More Dilution To Come  2020/01/24 13:13:01 Seeking Alpha
GNPX rose substantially on the announcement that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy. GNPX has an open $25 million shelf
   Genprex's stock rallies on FDA fast-track designation  2020/01/22 15:54:00 MarketWatch
Shares of Genprex Inc. climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental…

calendar